PeptiDex
Peptide Research Index
Research-backed
Peptide Research Index
⚠️ Educational only · Not medical advice · Consult a doctor · Most peptides are research-only / not FDA-approved for human use
⚠️ Educational only · Not medical advice · Consult a doctor · Most peptides are research-only / not FDA-approved for human use
Also: ACTH(4-7)-PGP
🧠Cognitive PeptideBDNF upregulation, nootropic effects. Enhances neural plasticity, protects neurons from oxidative stress, and improves cerebral blood circulation.
Human trial showing cognitive improvement including enhanced attention, memory formation, and learning capacity.
moderateDolotov et al. demonstrate Semax significantly upregulates BDNF and its receptor TrkB in the rat hippocampus, providing mechanistic basis for its nootropic effects.
preclinicalClinical-electrophysiologic studies report high efficacy of Semax in acute ischemic stroke patients, with significant neuroprotective effects and improved functional recovery.
moderate strongMolecular study showing Semax modulates expression of multiple neurotrophin genes including BDNF and nerve growth factor, supporting its broad neuroprotective mechanism.
preclinicalfMRI study in healthy individuals demonstrates Semax modulates brain functional connectivity networks, providing imaging evidence for its nootropic effects.
moderateNasal spray common; well-tolerated. Approved in Russia/Ukraine. Not FDA-approved in the US.
⚠️ For educational purposes only. Not medical advice. Consult a healthcare professional before using any peptide.
Nasal spray: 1-2 sprays per nostril. Can cycle 5 days on/2 off.
Last updated: 2026-01 · Laws change frequently. Verify current status in your jurisdiction.
Week 1
Noticeable cognitive enhancement: sharper focus, mental clarity, faster recall within days
Weeks 2-4
BDNF-mediated improvements in memory consolidation and mood stability
Month 2-3
Neuroprotective adaptation; reduced cognitive fatigue under stress
Long-term
Sustained cognitive baseline improvement; may support neurogenesis
| Side Effect | Incidence | Severity |
|---|---|---|
Nasal irritation Intranasal administration only | ~8% of users | mild |
Mild headache | ~5% of users | mild |
Irritability at high doses | ~3% of users | mild |
Incidence rates sourced from published clinical trial data where available; otherwise based on community research observations.
Weekly Peptide Research
New studies · vendor alerts · protocol tips
No spam. Unsubscribe anytime. Research use only.